British American Tobacco: Citi reiterates 'buy' as CAGNY debut underlines 2026 top pick

Citigroup reiterated a 'buy' on British American Tobacco and named it its top 2026 Staples pick after a confident CAGNY presentation in which management outlined a multi-category transformation into Modern Oral (notably Velo), Vapour and heated tobacco while retaining combustibles as the cash engine to fund the shift. Citi cited improving U.S. regulatory dynamics and easing one-off headwinds to organic sales growth, saying resilient combustibles cash flow plus momentum in new categories create upside optionality and potential rerating. Shares traded up 0.8% at 4,380p in afternoon trade.

Analysis

Market structure: Citi's reiteration crystallises a two‑tier winner set — incumbents with multi‑category exposure (BATS) and pouch/vapour suppliers — while pure combustibles players without clear reduced‑risk product (RRP) pathways are relative losers. Expect share gains in Modern Oral (Velo) and Vapour over 12–24 months, pressuring pricing power in mass combustible products and forcing promotional competition; if Velo sustains +20–30% annual OSG in core markets, BTI can capture meaningful share versus peers.

Risk assessment: Key tail risks are abrupt U.S. regulatory reversals (flavour/pouch bans) or a consumer shift back to combustibles reducing RRP take‑up; assign ~15% probability to a restrictive FDA action within 18 months that would erase >€0.5bn in revenue. Near term (days–weeks) expect muted moves on Citi commentary; medium term (3–12 months) volatility driven by quarterly OSG prints and regulatory headlines; long term (2–5 years) execution risk hinges on combustibles cashflow sustaining R&D/marketing for RRPs.

Trade implications: Primary trade is a constructive long on BATS (LSE:BATS) sized 1–3% of portfolio with a 12‑month target +20–30% conditional on OSG recovery and regulatory clarity; hedge with a capped downside using 12‑18 month call spreads or 3–6 month collars. Relative play: pair long BATS vs short PM (NYSE:PM) or MO (NYSE:MO) to express company‑specific RRP momentum — size neutralize market beta and take profits on divergence >8% over 3 months.

Contrarian angles: Consensus underweights the funding dynamic — combustibles still deliver cash to fuel RRPs — so a sharper combustibles decline would paradoxically slow RRP rollout and rerating. The market may underprice regulatory binary outcomes; consider that a 10–20% pullback in BATS on adverse FDA signals creates a high‑conviction buying window rather than a structural sell signal.

Key Decisions for Investors

• Establish a 2% long position in British American Tobacco (LSE:BATS) within 2 weeks, target 12‑month upside of 20–30% (from ~4,380p to ~5,250–5,700p); set a hard stop‑loss at 12% below entry and trim half position if OSG (organic sales growth) falls below +5% YoY on next two quarterly prints.
• Implement a 12‑18 month bull call spread on BATS: buy Jan 2027 4,300p call and sell Jan 2027 5,400p call sized to risk 0.5–1% of portfolio capital to capture rerating while limiting downside; close if spread value halves or if FDA issues formal restrictive guidance on pouches.
• Execute a pair trade: long BATS 1.5% vs short PM (NYSE:PM) 1.5% to isolate RRP execution; target relative outperformance of 8% over 3–6 months, unwind if the spread moves against >6% or if PM reports stronger RRP conversion (IQOS) metrics.
• Sell 3‑month covered calls representing 1–2% annualised yield on existing BATS holdings (e.g., sell near‑the‑money 3‑month calls at ~4,600–4,800p) to generate income while awaiting regulatory clarity; avoid if planning to scale into long position within 30 days.
• Hedge material FX exposure for positions >2% of portfolio by buying USD/GBP forwards or options if USD strengthens >2% from current levels, since stronger USD inflates reported revenues for BATS and can distort short‑term performance; reassess after next quarterly report.